JP2019535651A5 - - Google Patents

Download PDF

Info

Publication number
JP2019535651A5
JP2019535651A5 JP2019517873A JP2019517873A JP2019535651A5 JP 2019535651 A5 JP2019535651 A5 JP 2019535651A5 JP 2019517873 A JP2019517873 A JP 2019517873A JP 2019517873 A JP2019517873 A JP 2019517873A JP 2019535651 A5 JP2019535651 A5 JP 2019535651A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
seq
patient
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019517873A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019535651A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/055055 external-priority patent/WO2018067646A1/en
Publication of JP2019535651A publication Critical patent/JP2019535651A/ja
Publication of JP2019535651A5 publication Critical patent/JP2019535651A5/ja
Pending legal-status Critical Current

Links

JP2019517873A 2016-10-04 2017-10-04 Tie2シグナル伝達を活性化するための化合物及び方法 Pending JP2019535651A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662403786P 2016-10-04 2016-10-04
US62/403,786 2016-10-04
PCT/US2017/055055 WO2018067646A1 (en) 2016-10-04 2017-10-04 Compounds and methods for activating tie2 signaling

Publications (2)

Publication Number Publication Date
JP2019535651A JP2019535651A (ja) 2019-12-12
JP2019535651A5 true JP2019535651A5 (enExample) 2020-11-19

Family

ID=61832135

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019517873A Pending JP2019535651A (ja) 2016-10-04 2017-10-04 Tie2シグナル伝達を活性化するための化合物及び方法

Country Status (14)

Country Link
US (1) US20190225670A1 (enExample)
EP (1) EP3522906B1 (enExample)
JP (1) JP2019535651A (enExample)
KR (1) KR20190066040A (enExample)
CN (1) CN110177563A (enExample)
AU (1) AU2017339970A1 (enExample)
BR (1) BR112019006735A2 (enExample)
CA (1) CA3038809A1 (enExample)
EA (1) EA201990868A1 (enExample)
IL (1) IL265694A (enExample)
MX (1) MX2019003895A (enExample)
SG (1) SG10202103032QA (enExample)
WO (1) WO2018067646A1 (enExample)
ZA (1) ZA201902344B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101482483B1 (ko) 2006-04-07 2015-01-15 에르피오 세러퓨틱스 인코포레이티드 인간 단백질 타이로신 포스파타아제 베타(hptp베타)에 결합하는 항체 및 그의 용도
CA2850830A1 (en) 2011-10-13 2013-04-18 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome and cancer
CA3063140A1 (en) * 2017-05-08 2018-11-15 Asclepix Therapeutics, Inc. Biodegradable microparticles for sustained delivery of anti-angiogenic peptide
WO2019028427A1 (en) 2017-08-03 2019-02-07 Asclepix Therapeutics, Llc. METHODS OF IDENTIFYING AND PREPARING PHARMACEUTICAL AGENTS TO ACTIVATE TIE2 RECEPTOR
US10894824B2 (en) 2018-09-24 2021-01-19 Aerpio Pharmaceuticals, Inc. Multispecific antibodies that target HPTP-β (VE-PTP) and VEGF
US12540171B2 (en) 2019-03-26 2026-02-03 Asclepix Therapeutics, Inc. Compositions and methods for treating ocular disease
CN116854773A (zh) * 2022-03-23 2023-10-10 杭州禾泰健宇生物科技有限公司 一种多肽类化合物及其应用
CN117126233A (zh) * 2022-05-20 2023-11-28 杭州禾泰健宇生物科技有限公司 一种类肽化合物及其应用
WO2024044745A2 (en) * 2022-08-26 2024-02-29 Asclepix Therapeutics, Inc. Formulations for intraocular delivery of peptides derived from type iv collagen
KR20240133892A (ko) * 2023-02-28 2024-09-05 주식회사 파멥신 전신 모세혈관 누출 증후군의 예방 또는 치료용 조성물
KR102932502B1 (ko) 2023-07-11 2026-03-04 재단법인 아산사회복지재단 Tie2을 과발현하는 혈관내피세포를 포함하는 망막 내 혈관신생 질환 예방 또는 치료용 조성물

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR970002255B1 (ko) 1990-06-11 1997-02-26 넥스스타 파아마슈티컬드, 인크. 핵산 리간드
SE9400088D0 (sv) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
EP0773952B1 (en) 1994-07-20 2003-11-12 The General Hospital Corporation Interaction trap systems for detecting protein interactions
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
AUPP221098A0 (en) 1998-03-06 1998-04-02 Diatech Pty Ltd V-like domain binding molecules
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
CA2372464C (en) 1999-05-05 2012-07-31 Phylogica Limited Isolating biological modulators from biodiverse gene fragment libraries
ATE488584T1 (de) 1999-05-26 2010-12-15 Next Biomed Technologies Nbt Oy Verfahren und materialien zur erzeugung von sh3 domänen mit angepassten bindungseigenschaften
SE0001877D0 (sv) 2000-05-22 2000-05-22 Klaus Mosbach Molecular imprinting
JP5291279B2 (ja) 2000-09-08 2013-09-18 ウニヴェルジテート・チューリッヒ 反復モジュールを含む反復タンパク質の集合体
DE10053224A1 (de) 2000-10-26 2002-05-08 Univ Goettingen Georg August Verfahren zur Exposition von Peptiden und Polypeptiden auf der Zelloberfläche von Bakterien
EP2284270A3 (en) 2000-12-13 2012-07-25 Anaphore, Inc. Method for the identification and isolation of binding polypeptides from combinatorial libraries of proteins having the scaffold structure of C-type lectin-like domains
BR0212256A (pt) 2001-08-30 2004-08-31 Biorexis Pharmaceutical Corp Proteìnas de fusão de transferrina modificadas
MXPA05003493A (es) 2002-10-02 2005-09-30 Catalyst Biosciences Metodos para generar y seleccionar proteasas con especificidad alterada.
JP2007524348A (ja) 2003-01-07 2007-08-30 ダイアックス、コープ クニッツドメインライブラリー
US20060008844A1 (en) 2004-06-17 2006-01-12 Avidia Research Institute c-Met kinase binding proteins
DE102004049479A1 (de) 2004-10-11 2006-04-13 Scil Proteins Gmbh Proteinkonjugate zur Verwendung in Therapie, Diagnose und Chromatographie
US20100144641A1 (en) * 2005-09-12 2010-06-10 Popel Aleksander S Compositions Having Antiangiogenic Activity and Uses Thereof
EP1892248A1 (en) 2006-08-21 2008-02-27 Eidgenössische Technische Hochschule Zürich Specific and high affinity binding proteins comprising modified SH3 domains of FYN kinase
CN103897063B (zh) 2007-06-01 2017-04-12 马里兰大学巴尔的摩分校 免疫球蛋白恒定区Fc受体结合剂
ES2554812T3 (es) * 2007-11-09 2015-12-23 Genentech, Inc. Composiciones de antagonistas de quinasa 1 de tipo receptor de activina y métodos de uso
US9051349B2 (en) 2007-11-21 2015-06-09 Alba Therapeutics Corporation Larazotide acetate compositions
EP2451459B1 (en) * 2009-07-07 2017-11-22 Normoxys, Inc. Method of reducing multi-drug resistance using inositol tripyrophosphate
WO2012079088A2 (en) 2010-12-10 2012-06-14 The Johns Hopkins University Mimetic peptides derived from collagen type iv and their use for treating angiogenesis- and lymphangiogenesis- dependent diseases
WO2013086500A1 (en) 2011-12-09 2013-06-13 The Johns Hopkins University Artificial antigen presenting cells having a defined and dynamic shape
CN105431162B (zh) * 2013-06-07 2019-12-10 约翰霍普金斯大学 用于治疗血管生成依赖性和淋巴管生成依赖性疾病的生物模拟肽和生物可降解的递送平台

Similar Documents

Publication Publication Date Title
HRP20201842T1 (hr) Liječenje amd korištenjem aav2 varijante s afliberceptom
JP2017533201A5 (enExample)
JP2016065094A5 (enExample)
JP2019194251A5 (enExample)
JP2016516073A5 (enExample)
RU2018142768A (ru) Варианты капсидов аденоассоциированного вируса и способы их применения
JP2019196370A5 (enExample)
JP2016528202A5 (enExample)
FI3227675T3 (fi) Aktiviini-actrii-antagonisteja ja niiden käyttöjä myelodysplastisen oireyhtymän hoitamiseksi
Hennig et al. Nanoparticles for the treatment of ocular neovascularizations
JP2016521712A5 (enExample)
NZ595063A (en) Polypeptides from neisseria meningitidis
JP2015517488A5 (enExample)
JP2018505882A5 (enExample)
JP2017503014A5 (enExample)
JP2016536369A5 (enExample)
JP2020518651A5 (enExample)
JP2016517421A5 (enExample)
MX2019005466A (es) Composiciones y metodos para tratar diabetes, hipertension e hipercolesterolemia.
JP2015502389A5 (enExample)
JP2020518287A5 (enExample)
JP2015532293A5 (ja) 糖尿病患者における心不全の治療用組成物
JP2018530574A5 (enExample)
JP2022527276A5 (enExample)
JP2018536650A5 (enExample)